Loss of PADI2 and PADI4 ameliorates sepsis-induced acute lung injury by suppressing NLRP3+ macrophages

被引:1
|
作者
Yu, Xin [1 ]
Song, Yujing [1 ,2 ]
Dong, Tao [1 ,3 ]
Ouyang, Wenlu [1 ]
Shao, Liujiazi
Quan, Chao
Lee, kyung Eun
Tan, Tao
Tsung, Allan
Kurabayashi, Katsuo [2 ,4 ]
Alam, Hasan B.
Zhang, Mao
Ma, Jianjie
Li, Yongqing [1 ]
机构
[1] Univ Michigan Hlth Syst, Dept Surg, Ann Arbor, MI USA
[2] NYU, Dept Mech & Aerosp Engn, Brooklyn, NY USA
[3] Xu Zhou Med Univ, Sch Anesthesiol, Xuzhou, Jiangsu, Peoples R China
[4] NYU, Dept Chem & Biomol Engn, Brooklyn, NY USA
关键词
MACROPHAGE POLARIZATION; INFLAMMASOME ACTIVATION; SHOCK; DEIMINASES; RESIDENT;
D O I
10.1172/jci.insight.181686
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Sepsis-induced acute lung injury (ALI) is prevalent in patients with sepsis and has a high mortality rate. Peptidyl arginine deiminase 2 (PADI2) and PADI4 play crucial roles in mediating the host's immune response in sepsis, but their specific functions remain unclear. Our study shows that Padi2(-/-) Padi4(-/-) double KO (DKO) improved survival, reduced lung injury, and decreased bacterial load in Pseudomonas aeruginosa (PA) pneumonia-induced sepsis mice. Using single-cell RNA-Seq (scRNA-Seq), we found that the deletion of Padi2 and Padi4 reduced the Nlrp3(+) proinflammatory macrophages and fostered Chil3(+) myeloid cell differentiation into antiinflammatory macrophages. Additionally, we observed the regulatory role of the NLRP3/Ym1 axis upon DKO, confirmed by Chil3 knockdown and Nlrp3-KO experiments. Thus, eliminating Padi2 and Padi4 enhanced the polarization of Ym1(+) M2 macrophages by suppressing NLRP3, aiding in inflammation resolution and lung tissue repair. This study unveils the PADIs/NLRP3/Ym1 pathway as a potential target in treatment of sepsis-induced ALI.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Artesunate ameliorates sepsis-induced acute lung injury by activating the mTOR/AKT/PI3K axis
    Zhang, Ensheng
    Wang, Jing
    Chen, Qian
    Wang, Zhaohao
    Li, Dong
    Jiang, Ning
    Ju, Xiuli
    GENE, 2020, 759
  • [22] Resveratrol alleviates sepsis-induced acute lung injury by suppressing inflammation and apoptosis of alveolar macrophage cells
    Yang, Lei
    Zhang, Zhen
    Zhuo, Yuzhen
    Cui, Lihua
    Li, Caixia
    Li, Dihua
    Zhang, Shukun
    Cui, Naiqiang
    Wang, Ximo
    Gao, Hongwei
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2018, 10 (07): : 1961 - 1975
  • [23] L-lysine ameliorates sepsis-induced acute lung injury in a lipopolysaccharide-induced mouse model
    Zhang, Yang
    Wu, Yu
    Han, Dong
    Meng, Jing
    Wang, Hongjun
    Cao, Guangke
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 118
  • [26] Genetic Inactivation of the Phospholipase A2 Activity of Prdx6 Ameliorates Sepsis-induced Acute Lung Injury
    Vazquez-Medina, Jose Pablo
    Tao, Jian-Quin
    Patel, Priyal
    Bannitz-Fernandes, Renata
    Dodia, Chandra
    Sorokina, Elena
    Feinstein, Sheldon I.
    Chatterjee, Shampa
    Fisher, Aron
    FREE RADICAL BIOLOGY AND MEDICINE, 2017, 112 : 208 - 209
  • [27] Andrographolide ameliorates sepsis-induced acute lung injury by promoting autophagy in alveolar macrophages via the RAGE/PI3K/AKT/ mTOR pathway
    Qin, Yuping
    Li, Wenjuan
    Liu, Jinglun
    Wang, Fenglin
    Zhou, Wushuang
    Xiao, Linlin
    Zhou, Pengfei
    Wu, Fan
    Chen, Xiaoying
    Xu, Shan
    Liu, Lei
    Xiao, Xiaoqiu
    Zhang, Dan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 139
  • [28] Protective role of ILC2 in sepsis-induced acute lung injury
    Shu, Qiang
    Lai, Dengming
    Fan, Jie
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [29] Inhibition of STAT3 phosphorylation by colchicine regulates NLRP3 activation to alleviate sepsis-induced acute lung injury
    Liu, Yuanshui
    Yang, Hang
    Zhu, Fei
    Ouyang, Yanhong
    Pan, Pinhua
    INFLAMMOPHARMACOLOGY, 2023, 31 (04) : 2007 - 2021
  • [30] Inhibition of STAT3 phosphorylation by colchicine regulates NLRP3 activation to alleviate sepsis-induced acute lung injury
    Yuanshui Liu
    Hang Yang
    Fei Zhu
    Yanhong Ouyang
    Pinhua Pan
    Inflammopharmacology, 2023, 31 : 2007 - 2021